1887

Journal of Medical Microbiology logo

Volume 72, Issue 8

Molecular characterization and genotyping of isolates from cancer patients with infection or asymptomatic colonization No Access

Abstract

Cancer patients with infection (CDI) are at a higher risk for adverse outcomes. In addition, a high prevalence of asymptomatic colonization (CDAC) has been reported in this vulnerable population.

The molecular characteristics and potential role of CDAC in healthcare-related transmission in the cancer population have been poorly explored.

We aimed to compare the molecular and genotypic characteristics of isolates from cancer patients with CDAC and CDI.

We conducted a prospective cohort study of cancer patients with CDAC or CDI from a referral centre. Molecular characterization, typification and gene expression of isolates were performed.

The hospital-onset and community-onset healthcare facility-associated CDI rates were 4.5 cases/10 000 patient-days and 1.4 cases/1 000 admissions during the study period. Fifty-one strains were isolated: 37 (72 %) and 14 (28 %) from patients with CDI or CDAC, respectively. All isolates from symptomatic patients were , and four (10 %) were . In the CDAC group, 10 (71 %) isolates were toxigenic, and none were +. The Δ18 in-frame deletion and two transition mutations were found in five isolates. After bacterial typing, 60 % of toxigenic isolates from asymptomatic carriers were clonal to those from patients with -associated diarrhoea. No NAP1/027/BI strains were detected.

We found a clonal association between isolates from patients with CDAC and CDI. Studies are needed to evaluate the potential role of asymptomatic carriers in the dynamics of nosocomial transmission to support infection control measures and reduce the burden of CDI in high-risk groups.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): asymptomatic carriers , asymptomatic colonization , asymptomatic infection , C. difficile , cancer and Clostridioides difficile infection
© 2023 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001748
2023-08-25
2024-05-17
Loading full text...

Full text loading...

References

  1. Crobach MJT, Vernon JJ, Loo VG, Kong LY, Péchiné S et al. Understanding Clostridium difficile colonization. Clin Microbiol Rev 2018; 31:e00021–17 [View Article]
     [Google Scholar]
  2. Kuijper EJ, Coignard B, Tüll P et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 Suppl 6:2–18 [View Article] [PubMed]
     [Google Scholar]
  3. Guh AY, Mu Y, Winston LG, Johnston H, Olson D et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020; 382:1320–1330 [View Article] [PubMed]
     [Google Scholar]
  4. Zheng Y, Luo Y, Lv Y, Huang C, Sheng Q et al. Clostridium difficile colonization in preoperative colorectal cancer patients. Oncotarget 2017; 8:11877–11886 [View Article]
     [Google Scholar]
  5. Cannon CM, Musuuza JS, Barker AK, Duster M, Juckett MB et al. Risk of Clostridium difficile infection in hematology-oncology patients colonized with toxigenic C. difficile. Infect Control Hosp Epidemiol 2017; 38:718–720 [View Article]
     [Google Scholar]
  6. Abt MC, McKenney PT, Pamer EG. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol 2016; 14:609–620 [View Article] [PubMed]
     [Google Scholar]
  7. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66:e1–e48 [View Article] [PubMed]
     [Google Scholar]
  8. Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol 2008; 46:1996–2001 [View Article] [PubMed]
     [Google Scholar]
  9. Terhes G, Urbán E, Sóki J, Hamid KA, Nagy E. Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 2004; 42:4316–4318 [View Article] [PubMed]
     [Google Scholar]
  10. Persson S, Jensen JN, Olsen KEP. Multiplex PCR method for detection of Clostridium difficile tcdA, tcdB, cdtA, and cdtB and internal in-frame deletion of tcdC. J Clin Microbiol 2011; 49:4299–4300 [View Article] [PubMed]
     [Google Scholar]
  11. Knetsch CW, Bakker D, de Boer RF, Sanders I, Hofs S et al. Comparison of real-time PCR techniques to cytotoxigenic culture methods for diagnosing Clostridium difficile infection. J Clin Microbiol 2011; 49:227–231 [View Article] [PubMed]
     [Google Scholar]
  12. de Boer RF, Wijma JJ, Schuurman T, Moedt J, Dijk-Alberts BG et al. Evaluation of a rapid molecular screening approach for the detection of toxigenic Clostridium difficile in general and subsequent identification of the tcdC Δ117 mutation in human stools. J Microbiol Methods 2010; 83:59–65 [View Article] [PubMed]
     [Google Scholar]
  13. Ke S, Pollock NR, Wang X-W, Chen X, Daugherty K et al. Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection. Gut Microbes 2021; 13:1–18 [View Article] [PubMed]
     [Google Scholar]
  14. Pollock NR, Banz A, Chen X, Williams D, Xu H et al. Comparison of Clostridioides difficile stool toxin concentrations in adults with symptomatic infection and asymptomatic carriage using an ultrasensitive quantitative immunoassay. Clin Infect Dis 2019; 68:78–86 [View Article] [PubMed]
     [Google Scholar]
  15. Fatima R, Aziz M. The hypervirulent strain of Clostridium difficile: NAP1/B1/027 - a brief overview. Cureus 2019; 11:e3977 [View Article] [PubMed]
     [Google Scholar]
  16. Dupuy B, Govind R, Antunes A, Matamouros S. Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol 2008; 57:685–689 [View Article] [PubMed]
     [Google Scholar]
  17. Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator Tcdc: Tcdc inhibits C. difficile toxin expression. Mol Microbiol 2007; 64:1274–1288 [View Article]
     [Google Scholar]
  18. Murray R, Boyd D, Levett PN, Mulvey MR, Alfa MJ. Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. BMC Infect Dis 2009; 9:103 [View Article] [PubMed]
     [Google Scholar]
  19. Curry SR, Marsh JW, Muto CA, O’Leary MM, Pasculle AW et al. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 2007; 45:215–221 [View Article] [PubMed]
     [Google Scholar]
  20. Dávila LP, Garza-González E, Rodríguez-Zulueta P, Morfín-Otero R, Rodríguez-Noriega E et al. Increasing rates of Clostridium difficile infection in Mexican hospitals. Braz J Infect Dis 2017; 21:530–534 [View Article] [PubMed]
     [Google Scholar]
  21. De-la-Rosa-Martinez D, Rivera-Buendía F, Cornejo-Juárez P, García-Pineda B, Nevárez-Luján C et al. Risk factors and clinical outcomes for Clostridioides difficile infections in a case control study at a large cancer referral center in Mexico. Am J Infect Control 2022S0196-6553(22)00073-6 [View Article] [PubMed]
     [Google Scholar]
  22. Wilcox MH, Shetty N, Fawley WN, Shemko M, Coen P et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis 2012; 55:1056–1063 [View Article] [PubMed]
     [Google Scholar]
  23. Spigaglia P. Clostridioides difficile infection (CDI) during the COVID-19 pandemic. Anaerobe 2022; 74:102518 [View Article] [PubMed]
     [Google Scholar]
  24. Halstead FD, Ravi A, Thomson N, Nuur M, Hughes K et al. Whole genome sequencing of toxigenic Clostridium difficile in asymptomatic carriers: insights into possible role in transmission. J Hosp Infect 2019; 102:125–134 [View Article] [PubMed]
     [Google Scholar]
  25. Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 2013; 57:1094–1102 [View Article] [PubMed]
     [Google Scholar]
  26. Donskey CJ, Sunkesula VCK, Stone ND, Gould CV, McDonald LC et al. Transmission of Clostridium difficile from asymptomatically colonized or infected long-term care facility residents. Infect Control Hosp Epidemiol 2018; 39:909–916 [View Article] [PubMed]
     [Google Scholar]
  27. Worley J, Delaney ML, Cummins CK, DuBois A, Klompas M et al. Genomic determination of relative risks for Clostridioides difficile infection from asymptomatic carriage in intensive care unit patients. Clin Infect Dis 2021; 73:e1727–e1736 [View Article] [PubMed]
     [Google Scholar]
  28. Kong LY, Eyre DW, Corbeil J, Raymond F, Walker AS et al. Clostridium difficile: investigating transmission patterns between infected and colonized patients using whole genome sequencing. Clin Infect Dis 2019; 68:204–209 [View Article] [PubMed]
     [Google Scholar]
  29. Blixt T, Gradel KO, Homann C, Seidelin JB, Schønning K et al. Asymptomatic carriers contribute to nosocomial Clostridium difficile infection: a cohort study of 4508 patients. Gastroenterology 2017; 152:1031–1041 [View Article] [PubMed]
     [Google Scholar]
  30. Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis 2012; 31:3163–3171 [View Article] [PubMed]
     [Google Scholar]
  31. Longtin Y, Paquet-Bolduc B, Gilca R, Garenc C, Fortin E et al. Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of C difficile infections: a quasi-experimental controlled study. JAMA Intern Med 2016; 176:796–804 [View Article] [PubMed]
     [Google Scholar]
  32. Gilboa M, Houri-Levi E, Cohen C, Tal I, Rubin C et al. Environmental shedding of toxigenic Clostridioides difficile by asymptomatic carriers: a prospective observational study. Clin Microbiol Infect 2020; 26:1052–1057 [View Article] [PubMed]
     [Google Scholar]
  33. Fishbein SRS, Hink T, Reske KA, Cass C, Struttmann E et al. Randomized controlled trial of oral vancomycin treatment in Clostridioides difficile-colonized patients. mSphere 2021; 6:e00936-20 [View Article] [PubMed]
     [Google Scholar]
  34. Arimoto J, Horita N, Kato S, Fuyuki A, Higurashi T et al. Diagnostic test accuracy of glutamate dehydrogenase for Clostridium difficile: systematic review and meta-analysis. Sci Rep 2016; 6:29754 [View Article] [PubMed]
     [Google Scholar]
  35. Neoh H-M, Tan X-E, Sapri HF, Tan TL. Pulsed-field gel electrophoresis (PFGE): a review of the “gold standard” for bacteria typing and current alternatives. Infect Genet Evol 2019; 74:103935 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001748
Loading
Molecular characterization and genotyping of isolates from cancer patients with Clostridioides difficile infection or asymptomatic colonization
J. Med. Microbiol. 72, 001748 (2023); https://doi.org/10.1099/jmm.0.001748
/content/journal/jmm/10.1099/jmm.0.001748
/content/journal/jmm/10.1099/jmm.0.001748
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error